Tango Therapeutics appoints Sung H. Lee to Board; grants option for 60k shares at $8.93

Tango Therapeutics, Inc.

Board expanded to 8; Lee appointed as Class I director, term until 2028 annual meeting.
Lee to receive stock option for 60,000 shares at $8.93, vesting monthly over 3 years.
Lee to receive RSU for 10,000 shares vesting annually over 3 years; $40k annual retainer.
Lee is EVP & CFO at Cytokinetics, previously CFO at Vir, MorphoSys, Sangamo; 20+ yrs finance experience.
CEO says Lee's expertise will support lead program vopimetostat in registrational studies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.